Stock RDG READ-GENE S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Read-Gene S.A.

Equities

RDG

PLRADGN00014

Biotechnology & Medical Research

End-of-day quote Warsaw S.E.
Other stock markets
 03:30:00 12/06/2024 am IST 		5-day change 1st Jan Change
4.77 PLN 0.00% Intraday chart for Read-Gene S.A. +0.63% -17.76%
14/05 Read-Gene S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
12/02 Read-Gene S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 5.306 7.781 30.65 33.13 30.42 68.38
Enterprise Value (EV) 1 0.297 1.939 29.35 31.74 28.1 70.25
P/E ratio 6.54 x 65.9 x 87.8 x 875 x 143 x -50.8 x
Yield - - - - - -
Capitalization / Revenue 0.74 x 1.22 x 5.05 x 5.13 x 4.2 x 6.74 x
EV / Revenue 0.04 x 0.3 x 4.84 x 4.92 x 3.88 x 6.92 x
EV / EBITDA 0.12 x 1.19 x 25.4 x 47.1 x 37.9 x -90.1 x
EV / FCF 0.14 x 2.21 x -6.17 x 102 x 573 x -55 x
FCF Yield 709% 45.3% -16.2% 0.98% 0.17% -1.82%
Price to Book 1.38 x 1.88 x 7.55 x 6.1 x 5.52 x 16.4 x
Nbr of stocks (in thousands) 11,790 11,790 11,790 11,790 11,790 11,790
Reference price 2 0.4500 0.6600 2.600 2.810 2.580 5.800
Announcement Date 10/05/19 01/06/20 01/06/21 31/05/22 31/05/23 23/05/24
1PLN in Million2PLN
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 7.125 6.366 6.069 6.454 7.241 10.15
EBITDA 1 2.434 1.63 1.154 0.6735 0.7422 -0.7797
EBIT 1 1.102 0.125 0.5033 0.1133 0.2863 -1.272
Operating Margin 15.47% 1.96% 8.29% 1.76% 3.95% -12.54%
Earnings before Tax (EBT) 1 0.8452 0.1372 0.3694 0.0526 0.0608 -1.624
Net income 1 0.8107 0.118 0.3492 0.0379 0.2132 -1.347
Net margin 11.38% 1.85% 5.75% 0.59% 2.94% -13.27%
EPS 2 0.0688 0.0100 0.0296 0.003213 0.0181 -0.1142
Free Cash Flow 1 2.105 0.8775 -4.756 0.3114 0.049 -1.278
FCF margin 29.54% 13.78% -78.37% 4.83% 0.68% -12.59%
FCF Conversion (EBITDA) 86.49% 53.82% - 46.24% 6.61% -
FCF Conversion (Net income) 259.64% 743.66% - 821.99% 22.99% -
Dividend per Share - - - - - -
Announcement Date 10/05/19 01/06/20 01/06/21 31/05/22 31/05/23 23/05/24
1PLN in Million2PLN
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - 1.87
Net Cash position 1 5.01 5.84 1.31 1.39 2.32 -
Leverage (Debt/EBITDA) - - - - - -2.398 x
Free Cash Flow 1 2.1 0.88 -4.76 0.31 0.05 -1.28
ROE (net income / shareholders' equity) 23.6% 2.96% 8.52% 0.8% 3.9% -27.8%
ROA (Net income/ Total Assets) 3.94% 0.47% 1.94% 0.45% 1.15% -5.17%
Assets 1 20.56 24.92 18.01 8.453 18.5 26.06
Book Value Per Share 2 0.3300 0.3500 0.3400 0.4600 0.4700 0.3500
Cash Flow per Share 2 0.4200 0.5000 0.6000 0.6000 0.6100 0.1400
Capex 1 0.12 0.15 0.07 0.06 0.01 0.36
Capex / Sales 1.63% 2.32% 1.11% 0.93% 0.2% 3.57%
Announcement Date 10/05/19 01/06/20 01/06/21 31/05/22 31/05/23 23/05/24
1PLN in Million2PLN
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Diagnostics & Testing

1st Jan change Capi.
READ-GENE S.A. Stock Read-Gene S.A.
-17.76% 1.41Cr
GUARDANT HEALTH, INC. Stock Guardant Health, Inc.
+17.71% 389.62Cr
IOVANCE BIOTHERAPEUTICS, INC. Stock Iovance Biotherapeutics, Inc.
+4.92% 238.7Cr
BGI GENOMICS CO., LTD. Stock BGI Genomics Co., Ltd.
-19.94% 201.42Cr
VERACYTE, INC. Stock Veracyte, Inc.
-19.77% 168.72Cr
MARAVAI LIFESCIENCES HOLDINGS, INC. Stock Maravai LifeSciences Holdings, Inc.
+20.31% 104.67Cr
CAREDX, INC Stock CareDx, Inc
+27.42% 80Cr
SEEGENE, INC. Stock Seegene, Inc.
-9.83% 70Cr
ADAPTIVE BIOTECHNOLOGIES CORPORATION Stock Adaptive Biotechnologies Corporation
-29.39% 51Cr
CURIOX BIOSYSTEMS CO., LTD Stock Curiox Biosystems Co., Ltd
-6.96% 27Cr
Bio Diagnostics & Testing
  1. Stock Market
  2. Equities
  3. RDG Stock
  4. Financials Read-Gene S.A.